Doherty James J. 4

What Happened

• James J. Doherty, President and Chief Development Officer of Acumen Pharmaceuticals (ABOS), was awarded two equity grants on 2026-01-16: 166,867 restricted stock units (RSUs) and a 250,300-share derivative award (option-like grant). Both grants show an acquisition price of $0.00 (i.e., awarded, not purchased).

Key Details

• Filing date: 2026-01-21; Reported transaction date: 2026-01-16.
• Grant amounts and price: 166,867 RSUs @ $0.00 (F1); 250,300 derivative award @ $0.00 (F2).
• Vesting/terms: F1 — RSUs vest in three equal annual installments beginning one year after the grant date, subject to continuous service. F2 — the derivative award vests in 48 equal monthly installments, fully vesting on the fourth anniversary, subject to continuous service.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Nature of transaction: Award/Grant (code A). No immediate sale or cashless exercise reported.
• Timeliness: Filing date is five days after the transaction date; Form 4s are normally due within two business days, so investors may want to note the timing.

Context

• These are standard equity compensation awards to an executive and do not represent an open-market purchase or sale. RSUs convert to common shares upon vesting; the derivative award vests monthly over four years. Such grants are common for executive retention and alignment with shareholders; they do not by themselves indicate immediate buying or selling activity.